BWI: Centaur Pharma launches an innovator’s formulation of Timolol Long Acting(Glucotim LA) in India in collaboration with Senju Pharma, Japan

Press release from Business Wire India
Source: Centaur Pharmaceuticals Private Limited
Monday, December 27, 2010 10:09 AM IST (04:39 AM GMT)
Editors: General: Consumer interest; Business: Advertising, PR & marketing, Business services, Healthcare, biotechnology & pharmaceutical, Retailers; Healthcare
--------------------------------------------------
Centaur Pharma launches an innovator's formulation of Timolol Long Acting(Glucotim LA) in India in collaboration with Senju Pharma, Japan


Mumbai, Maharashtra, India, Monday, December 27, 2010 -- (Business Wire India) -- WHO estimates 3.6% of prevalence of Glaucoma in India i.e 40 million Indians at risk of suffering from glaucoma. Hence there is need for an effective, well tested, convenient to use and affordable therapy for masses who are suffering from Glaucoma.

Centaur now joins hands with SENJU Pharma, a leading drug development company in the field of Ophthalmology in Japan to bring into India innovators formulations for the benefit of large population suffering form Glaucoma and other ophthalmologicals disorders.

SENJU Pharma, Japan, is the pioneer in ophthalmic formulations development and many of its ophthalmic formulations are leading brands in USA, Japan and other major Pharma markets.

Glucotim LA of Centaur Pharma is an original research formulation of Timolol Long Acting developed by Senju that is being introduced by Centaur for the first time in India at just rs.45/- per vial.

Glucotim LA offers the following benefits over currently available options in India-

. OD convenience
. Efficacy equivalent to Timolol BID
. Designed for rapid, continuous delivery
. 24 hrs effective IOP control
. Controls diurnal IOP fluctuations at peak and trough
. Well tolerated
. No gel induced blur
. ½ the cost of conventional Timolol therapy

Hence, Glucotim LA is the glaucoma therapy for masses offering best of Timolol formulations without pinching the patient's purse.

Centaur Pharma is all set to launch Glucotim LA in December 2010 in India.

About Centaur Pharmaceuticals Private Limited (www.centaurpharma.com )

Centaur was established in Mumbai, India, in 1978. Centaur ranks among India's Top 50 pharmaceutical players. In India, Centaur brands are leaders in 6 therapy segments, including the anticold segment, with Sinarest. Centaur is India's largest manufacturer and exporter of psychotropic API, with an USFDA approved facility. Centaur is strategically positioned in the contract manufacturing space with its UKMHRA and TGA, Australia, approved formulations facility in Pune. Centaur has built competencies in clinical research space with capabilities to conduct BA-BE studies and phase II/III/IV trials.

To view the photo kindly click on the link below:
Glucotim-LA
For picture(s)/data to illustrate this release click below:

http://www.BusinessWireIndia.com/attachments/Pic_1(370).jpg
Pic_1(370).jpg


CONTACT DETAILS
Prabhakar Bethi, General Manager (Marketing), Centaur Pharmaceuticals Private Limited, +91 (22) 66499153 / +91 9320053718, pbethi@centaurlab.com

KEYWORDS
CONSUMER, MARKETING, BUSINESS SERVICES, HEALTHCARE, RETAIL, HEALTHCARE

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com